Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086034 · ClinicalTrials.gov registry record · Phase 2
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00086034 is a Phase 2 study that has completed, run by Pharmacyclics. The registered enrollment target is 35 participants.
The verdict
NCT00086034, a Phase 2 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
Interventions
- DRUG Motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086034
The ClinicalTrials.gov registry entry for NCT00086034 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Motexafin gadolinium is the first listed.
NCT00086034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086034 about?
NCT00086034 is a clinical study titled "Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma". The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
What is the current status of trial NCT00086034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants.
What interventions are being tested in trial NCT00086034?
The interventions under investigation include: Motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00086034?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.